Core Viewpoint - PharmaCorp Rx Inc. reported strong operational momentum and financial results for Q2 2025, highlighting its national acquisition strategy and growth in pharmacy-level contributions [2][4]. Financial Highlights - The company generated revenues from three operating pharmacies, with same-store sales increasing by 11.3% year-over-year compared to Q2 2024 [8]. - Prescription volumes rose by 3.5% year-over-year, indicating sustained patient engagement [8]. - The net loss for the quarter was attributed to investments in corporate infrastructure and deferred executive compensation from 2024 [5][8]. Operational Update - Key investments were made in systems, personnel, and integration processes to support scalable national growth [5]. - The company completed the acquisition of its fourth pharmacy in Western Canada, enhancing its national footprint [6][8]. Subsequent Events - On August 13, 2025, PharmaCorp entered into a credit agreement with CIBC, providing up to $20.5 million in committed credit facilities to support its acquisition strategy [7]. - A separate $5 million credit facility was established to support the Pharmacist Co-Ownership Program, enabling pharmacists to acquire ownership positions [7]. Pipeline Progress - PharmaCorp is actively working to finalize purchase and sale agreements related to previously announced letters of intent, expecting to close additional transactions in the second half of the year [9]. Company Overview - PharmaCorp Rx Inc. focuses on empowering pharmacists to become equity partners while supporting the continuity of care and succession for retiring pharmacy owners [12]. - The company operates four PharmaChoice Canada bannered pharmacies and aims to acquire more pharmacies under this brand [12].

Core Points - Collective Metals Inc. has successfully closed a non-brokered private placement, issuing 4,368,333 units at a price of $0.06 per unit, resulting in total gross proceeds of $262,099.98 [1] - Each unit consists of one common share and one transferable common share purchase warrant, with the warrant allowing the purchase of an additional share at $0.08 for 24 months [1] - The proceeds from the offering will be utilized for general working capital purposes [2] Related Party Transaction - The offering is classified as a "related party transaction" as a director of the company subscribed for 200,000 units for $12,000 [3] - The company relied on exemptions from certain requirements of Multilateral Instrument 61-101 due to the fair market value of the securities issued not exceeding 25% of the company's market capitalization [3] - A material change report was not filed regarding the insider's participation as it was not determined prior to the offering's closing [3] Securities and Regulations - Shares issued under the offering will be subject to a statutory hold period of four months and one day from the issuance date [4] - The securities have not been registered under the U.S. Securities Act of 1933 and cannot be offered or sold in the U.S. without registration or an exemption [5] Company Overview - Collective Metals Inc. specializes in precious metals exploration in North America, with the Whitemud Project comprising 381 mining claims over 7,775 hectares [6]

TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX: CAR.UN) announced today its August 2025 monthly distribution in the amount of $0.12916 per Unit (or $1.55 on an annualized basis). The August 2025 distribution will be payable on September 15, 2025 to Unitholders of record at the close of business on August 29, 2025. CAPREIT is Canada’s largest publicly traded provider of quality rental housing. As at June 30, 2025, CAPREIT owns approximat ...

TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- European Residential Real Estate Investment Trust (TSX: ERE.UN, “ERES”) is pleased to announce that the trustees of ERES have declared the August 2025 monthly cash distribution of €0.005 per Unit and Class B LP Unit (the “August 2025 Distribution”), being equivalent to €0.06 per Unit annualized. The distribution will be payable to holders of the Units and Class B LP Units (the “Unitholders”) of record on August 29, 2025, with payment on September 15, 2025. The Euro ...

Hong Kong, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BUUU Group Limited (Nasdaq: BUUU) (the “Company”), an established meetings, incentives, conferences and exhibitions (“MICE”) solutions provider based in Hong Kong , today announced the closing of its initial public offering (the “Offering”) of 1,500,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $4.00 per Class A Ordinary Share (the “Offering Price”). The Class A Ordinary Shares commenced trading on the Nasdaq Capital Market on August ...

Core Viewpoint - BioSig Technologies, Inc. has successfully closed an underwritten public offering to support its merger with Streamex Exchange Corporation, focusing on gold tokenization infrastructure [1][2][3]. Group 1: Offering Details - The offering included 3,852,149 shares of common stock priced at $3.90 per share, generating gross proceeds of approximately $15,023,381 before expenses [2]. - The net proceeds will be utilized for purchasing gold bullion, general corporate purposes, and working capital [2]. Group 2: Strategic Intent - The CEO of BioSig emphasized the importance of aligning short and long-term capital strategies with high-quality shareholders to enhance shareholder value [3]. - The company aims to establish itself as a leader in the gold bullion-based real-world asset space, leveraging the recent capital raise [3]. Group 3: Company Background - Streamex is focused on building institutional-grade infrastructure for gold tokenization, supported by a gold-denominated treasury [6]. - BioSig Technologies is a medical device company known for its PURE EP™ Platform, which aids electrophysiologists in treating cardiovascular arrhythmias [7][8].

Core Viewpoint - Youxin Technology Ltd has received notices from Nasdaq regarding non-compliance with minimum bid price and market value requirements for continued listing on the Nasdaq Capital Market [1][2]. Compliance Requirements - The company has a compliance period of 180 days, until February 9, 2026, to meet the minimum bid price requirement of $1.00 per share for at least 10 consecutive business days [3]. - If the company fails to meet the minimum bid price requirement, it may be eligible for an additional 180-day grace period, provided it meets other listing standards [4]. - The company also has a separate 180-day compliance period to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35 million [5]. Business Operations - The receipt of the notices does not affect the company's business operations, and it intends to take measures to regain compliance with Nasdaq Listing Rules [6]. - Youxin Technology is a SaaS and PaaS provider focused on helping retail enterprises with digital transformation through cloud-based solutions [7].

Core Viewpoint - Foresight Autonomous Holdings Ltd. plans to conduct a reverse share split at a ratio of 1-for-7, effective on August 24, 2025, on the Tel-Aviv Stock Exchange and August 25, 2025, on the Nasdaq Capital Market [1][2]. Company Overview - Foresight Autonomous Holdings Ltd. is a technology company focused on developing advanced 3D perception systems and cellular-based applications [5]. - The company operates through subsidiaries including Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd., and Eye-Net Mobile Ltd., which develop both "in-line-of-sight" vision systems and "beyond-line-of-sight" accident-prevention solutions [5]. Reverse Share Split Details - The reverse share split will not change the existing ratio of ordinary shares represented by the Company's American Depositary Shares (ADSs) [2]. - Following the reverse share split, the ADS price is expected to increase proportionally, although there is no assurance that the post-split price will match the expected proportionate increase [2]. - The reverse share split aims to help the company maintain compliance with Nasdaq listing requirements, though success in this goal is not guaranteed [2]. Shareholder Impact - The reverse share split will not affect any shareholder's percentage ownership or voting power [4]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [4]. Product and Market Applications - Foresight's 3D perception systems include automatic calibration modules and dense 3D point clouds applicable in various markets such as automotive, defense, autonomous driving, agriculture, heavy industrial equipment, and unmanned aerial vehicles (UAVs) [6]. - Eye-Net Mobile focuses on developing next-generation vehicle-to-everything (V2X) collision prevention solutions, enhancing road safety and situational awareness through AI technology and existing cellular networks [7].

Company Overview - Brunswick Exploration Inc. is a Montreal-based mineral exploration company focused on grassroots exploration for lithium in Canada, which is essential for global decarbonization and energy transition [5]. Recent Developments - Brunswick Exploration has consolidated its ownership of eight mining claims at the Mirage project, now owning 100% of these claims following a purchase agreement with General Partnership Osisko Baie James dated August 15, 2025 [1]. - To facilitate this acquisition, Brunswick has renounced its option to acquire a 90% undivided interest in the Plex property, as per the third amendment to the option agreement with Osisko Baie James on the same date [2]. - As part of the termination of the Plex Property Option, Osisko Baie James will pay Brunswick Exploration $1,000,000 within 30 days of the publication of a technical report that presents a minimum of 1 million ounces of gold in measured, indicated, and/or inferred resources [3]. Shareholder Compensation - The company has granted 821,425 deferred share units (DSUs) to its non-executive directors in lieu of board fees, with a fair market value of $0.14 per DSU, vesting one year from the grant date [4].

Core Insights - Allarity Therapeutics has successfully initiated enrollment in an advanced Phase 2 clinical trial for ovarian cancer, focusing on recurrent, platinum-resistant or platinum-ineligible patients [1][6] - The company has expanded its global intellectual property (IP) protection by securing an Australian patent for the stenoparib DRP companion diagnostic, which includes 40 claims [5] - A new service contract has been secured with a European biotech for Allarity Medical Laboratory, enhancing revenue opportunities [1][10] Clinical and Drug Development Progress - The Phase 2 clinical trial for stenoparib is progressing well, with initial patient dosing reflecting strong engagement from investigators [6] - A partnership has been initiated with the Indiana Biosciences Research Institute to conduct advanced studies on the anti-cancer effects of stenoparib, potentially expanding its therapeutic applications [6] - The company is also advancing a Veterans Administration-funded combination trial of stenoparib and temozolomide in small cell lung cancer, with patient recruitment expected to begin in the second half of 2025 [10] Financial Performance - As of June 30, 2025, Allarity reported cash and cash equivalents of $17.8 million, down from $19.5 million at the end of 2024 [16] - The company reduced its accounts payable and accrued expenses by $2 million during the quarter, indicating improved financial management [2][10] - Research and Development (R&D) expenses for the second quarter of 2025 were $2.3 million, compared to $1.06 million in the same quarter of 2024, reflecting ongoing clinical advancement activities [10][18] Corporate and Strategic Developments - Allarity has made significant progress in strengthening its leadership team, with new appointments to the Board of Directors and executive positions [10] - The company has launched a refined monotherapy trial protocol for stenoparib, which is now steadily enrolling patients [3][10] - Allarity's DRP platform has been expanded to include a new DRP for the antibody therapy daratumumab, showcasing its broad applicability across various cancer types [10]